Bio-Rad Laboratories' stock has been the subject of several recent research reports. Analysts have given it a moderate buy rating, indicating a level of confidence in its future performance. The company will present at J.P. Morgan's upcoming Healthcare Conference in 2025. Short interest in the company's stock has risen by 12.9%, making it a subject of interest among investors. The stock showed a rising relative price strength. Positive financial performance and an attractive opportunity led to Bio-Rad's stock surge. The company just released its third-quarter results and analysts are updating their estimates. Nonetheless, shareholders endured a significant loss, resulting in a 14% decline in the stock price this week with three-year losses amounting to 53%. The company saw a robust growth with stock hitting 52-week high amid mixed outlook as per SWOT analysis. However, it cut annual revenue forecast on weak demand for diagnostics products. Bio-Rad's Q3 earnings surpassed estimates but 2024 revenue growth outlook was reiterated resulting in share slip. Further, the company reported second and third quarter financial results for 2024 with both earnings and revenues surpassing estimates. Lastly, the Q4 earnings forecast was cut by analysts while overall having a positive outlook for FY2024 earnings.
Bio-Rad Laboratories Stocks News Analytics from Thu, 21 Jun 2018 02:34:36 GMT to Fri, 03 Jan 2025 10:21:37 GMT -
Rating 3
- Innovation -5
- Information 7
- Rumor -4
